Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

IDH1-VAC (IDH1 R132H Peptide Vaccine)

NOA-16

German Cancer Research Center · Phase 1 · Completed · Enrollment 39

NCT02454634

ArmPopulationDoseEstimandComparatorEfficacy
IDH1-vacnewly diagnosed IDH1 R132H astrocytomanot stated in sourceSingle armn/rvaccine-induced immune response: 93.3%, 28 of 30 evaluable3-year PFS rate: 63%